BMR.H Bradmer Pharmaceuticals

NOT FOR DISTRIBUTION IN THE UNITED STATES OR FOR DISSEMINATION TO U.S. NEWS WIRE
SERVICES.


Bradmer Pharmaceuticals Inc. (TSX VENTURE:BMR.H) ("Bradmer") announced today
that it has entered into a letter of intent dated December 20, 2011 to complete
a business combination (the "Transaction") with Epic Production Technologies
International Inc. ("Epic"). The Transaction will be effected by way of a
three-cornered amalgamation, share exchange or similar transaction between
Bradmer and Epic (the resulting entity of the Transaction being referred to
herein as the "Resulting Issuer"). It is anticipated that the Resulting Issuer
will be named "Epic Production Technologies International Inc." or such other
name as may be determined by Epic. The Transaction is an arm's length
transaction and will constitute a reverse take-over and change of business under
applicable policies of the TSX Venture Exchange (the "TSX-V").


Established in 2008, Epic is a supplier of lighting, rigging, audio, video,
softgoods, system integration and project management to sports and entertainment
venues and the emerging field of 'architainment' (the hybrid of entertainment
and architecture). The company's lighting rental division specializes in concert
touring, theatre, and corporate and special events across the continent. Three
full-service North American facilities also provide a complete range of sales
and rental solutions for regional clients.


Bradmer is an OBCA company whose common shares are listed on the NEX Board of
the TSX-V.


In conjunction with, or prior to the closing of the Transaction, Epic, or an
affiliate of Epic, will complete a brokered private placement of subscription
receipts (the "Brokered Private Placement"). It is contemplated that the
subscription receipts issued in the Brokered Private Placement will be
ultimately convertible or exchangeable into freely tradeable common shares of
the Resulting Issuer (each a "Resulting Issuer Share"). For the purposes of the
Transaction, the deemed value of each currently outstanding common share of
Bradmer will be $0.22. The deemed enterprise value of Epic will be $20 million
on a pre-Brokered Private Placement basis. It is intended that no more than
100,000,000 Resulting Issuer Shares will be issued to current Epic shareholders
and Bradmer shareholders will be issued one (1) Resulting Issuer each one (1)
common share of Bradmer currently held.


The letter of intent is non-binding with respect to commercial terms, but
includes binding obligations typical in the circumstances, including those
relating to a period of exclusive dealing and confidentiality. The proposed
Transaction is subject to a number of terms and conditions, including the
entering into by the parties of a definitive agreement with respect to the
Transaction (such agreement to include representations, warranties, conditions
and covenants typical for a transaction of this nature), the completion of
satisfactory due diligence investigations, completion of the Brokered Private
Placement, the approval of the directors of each of Bradmer and Epic, the
approval of the shareholders of Bradmer, the approval of the securityholders of
Epic and the approval of the TSX-V and other applicable regulatory authorities.
The parties intend that the Resulting Issuer will be listed on the TSX-V as an
Industrial Issuer following completion of the Transaction. 


The parties are in the process of negotiating the definitive terms and the
structure of the Transaction and plan on issuing additional press releases and
updates in accordance with applicable rules of the TSX-V as the definitive
agreement is signed, due diligence is completed and other milestones are
achieved. The common shares of Bradmer will remain halted until the completion
of the Transaction or until otherwise determined by the TSX-V and its Regulation
Service Provider.


Completion of the Transaction is subject to a number of conditions, including
but not limited to satisfactory completion of a definitive agreement as well as
the completion of the Brokered Private Placement, TSX-V acceptance and, if
applicable pursuant to TSX-V requirements, majority of the minority shareholder
approval. Where applicable, the Transaction cannot close until the required
shareholder approval is obtained. There can be no assurance that the Transaction
will be completed as proposed or at all. Investors are cautioned that, except as
disclosed in the management information circular or filing statement to be
prepared in connection with the Transaction, any information released or
received with respect to the Transaction may not be accurate or complete and
should not be relied upon. Trading in the securities of a NEX should be
considered highly speculative. The TSX-V has in no way passed upon the merits of
the Transaction and has neither approved nor disapproved the contents of this
press release. 


The proposed Transaction is subject to the sponsorship requirements of the
TSX-V, unless an exemption from those requirements is granted by the TSX-V.
Bradmer intends to apply for an exemption from the sponsorship requirements;
however, there can be no assurance an exemption will be obtained. If an
exemption from the sponsorship requirements is not obtained, a sponsor will be
identified at a later date. An agreement to act as sponsor in respect of the
Transaction should not be construed as any assurance with respect to the merits
of the Transaction or the likelihood of its completion.


Cautionary Note Regarding Forward-Looking Statements

Certain statements contained in this news release may constitute forward-looking
information, within the meaning of Canadian securities laws. Forward-looking
information may relate to this news release and other matters identified in
Epic's and Bradmer's public filings, forward-looking information and anticipated
events or results and can be identified by terminology such as "may", "will",
"could", "should", "expect", "plan", "anticipate", "believe", "intend",
"estimate", "projects", "predict", "potential", "continue" or other similar
expressions concerning matters that are not historical facts and include, but
are not limited in any manner to, those with respect to capital and operating
expenditures, economic conditions, availability of sufficient financing, receipt
of approvals, satisfaction of closing conditions and any and all other timing,
development, operational, financial, economic, legal, regulatory and/or
political factors that may influence future events or conditions. Such
forward-looking statements are based on a number of material factors and
assumptions, including, but not limited in any manner, those disclosed in any
other public filings of Bradmer, and include the ultimate availability and final
receipt of required approvals, sufficient working capital for development and
operations, access to adequate services and supplies, availability of markets
for products, commodity prices, foreign currency exchange rates, interest rates,
access to capital markets and other sources of financing and associated cost of
funds, availability of a qualified work force, availability of manufacturing
equipment, no material changes to the tax and regulatory regime and the ultimate
ability execute its business plan on economically favorable terms. While we
consider these assumptions to be reasonable based on information currently
available to us, they may prove to be incorrect. Actual results may vary from
such forward-looking information for a variety of reasons, including but not
limited to risks and uncertainties disclosed in other Bradmer filings at
www.sedar.com and other unforeseen events or circumstances. Other than as
required by law, neither Epic nor Bradmer intends, and neither undertake any
obligation to update any forward looking information to reflect, among other
things, new information or future events.

Bradmer Pharmaceuticals (TSXV:BMR.H)
Historical Stock Chart
From May 2024 to Jun 2024

Bradmer Pharmaceuticals (TSXV:BMR.H)
Historical Stock Chart
From Jun 2023 to Jun 2024